TY - JOUR T1 - Platform for rapid nanobody discovery <em>in vitro</em> JF - bioRxiv DO - 10.1101/151043 SP - 151043 AU - Conor McMahon AU - Alexander S. Baier AU - Sanduo Zheng AU - Roberta Pascolutti AU - Janice X. Ong AU - Sarah C. Erlandson AU - Daniel Hilger AU - Aaron M. Ring AU - Aashish Manglik AU - Andrew C. Kruse Y1 - 2017/01/01 UR - http://biorxiv.org/content/early/2017/06/16/151043.abstract N2 - Camelid single-domain antibody fragments (“nanobodies”) provide the remarkable specificity of antibodies within a single immunoglobulin VHH domain. This unique feature enables applications ranging from their use as biochemical tools to therapeutic agents. Virtually all nanobodies reported to date have been obtained by animal immunization, a bottleneck restricting many applications of this technology. To solve this problem, we developed a fully in vitro platform for nanobody discovery based on yeast surface display of a synthetic nanobody scaffold. This platform provides a facile and cost-effective method for rapidly isolating nanobodies targeting a diverse range of antigens. We provide a blueprint for identifying nanobodies starting from both purified and non-purified antigens, and in addition, we demonstrate application of the platform to discover rare conformationally-selective nanobodies to a lipid flippase and a G protein-coupled receptor. To facilitate broad deployment of this platform, we have made the library and all associated protocols publicly available. ER -